Interactive Transcript
0:02
Hello, and welcome to Noon Conference hosted by Modality.
0:05
Noon Conference connects the global radiology community through free live
0:09
educational webinars that are accessible for all and is an opportunity to learn
0:13
alongside top radiologists from around the world.
0:15
Today, we are honored to welcome Dr.
0:17
Jyothi Veluga for a lecture entitled World Beyond PI-RADS: Updates in Prostate MRI.
0:23
Dr. Veluga completed her radiology residency in India and Singapore, and currently
0:27
she is an abdominal radiologist at St Vincent's Hospital, Sydney, with a
0:31
subspecialty focus on prostate and colorectal imaging.
0:35
At the end of the lecture, please join her in a Q&A session where she will address
0:38
questions you may have on today's topic.
0:41
Please remember to use that Q&A feature to submit your questions so we can get to
0:44
as many as we can before time is up. With that, ready to begin today's lecture, Dr.
0:49
Veluga, please take it from here.
0:52
Thank you, Ashley, for the kind introduction, and thank you, all of you, for being
0:56
here, giving me this opportunity to share space with you.
1:00
And also special thanks for moving the Noon Conference to evening, so that it's
1:06
morning time for me. So I'm based in Sydney, and this is the hospital
1:12
that I work in, St. Vincent's Hospital.
1:14
I'm currently sitting right here, and
1:19
this is the view from my apartment building, which is quite close to the hospital.
1:23
As you can see, there's a little bit of bay, and we've moved into spring now, so
1:27
really amazing weather. And in the next 30 to 40 minutes, we're going to look at
1:33
a few case examples of updates in prostate imaging.
1:38
I have no disclosures, and the objectives of this talk are essentially to
1:42
familiarize ourselves with different reporting systems that are available besides
1:46
PI-RADS, for example, for active surveillance or post-treatment assessments or even
1:51
image quality. So just as an introduction, we all are well-versed with PI-RADS
1:56
scoring. It's used in diagnosis of prostate cancer, especially to look at the
2:02
likelihood of a clinically significant prostate cancer.
2:06
But once we've identified the cancer and say we've treated it, the rules change,
2:11
and it may be difficult to apply the PI-RADS framework.
2:14
And there are also now scenario-based reporting systems that are available, which
2:19
we're going to look at those examples with a few cases.
2:24
So the first case I've got here is a 65-year-old male patient with positive family
2:29
history. He's on active surveillance.
2:31
So a quick word on what active surveillance actually means.
2:35
So this is an established management strategy for low risk or favorable
2:39
intermediate-risk prostate cancer.
2:41
That is, we're looking at 3+3 or favorable 3+4 lesions, and this usually involves
2:47
close monitoring through PSA, DRE examination, MRI, or plus-minus biopsy.
2:53
So the intent here is still curative, meaning we follow up these patients year on
2:57
year with still an intent to cure if things change.
3:02
So, coming back to the first case. So what you see here is, we see a focal area
3:09
at the right posterior peripheral zone.
3:11
It's T2 dark, and there's also a DWI, can't really assess much.
3:17
Its plus-minus image quality is not that great.
3:19
But in ADC, there's a little bit of low signal intensity.
3:23
So based on this, it would've been PI-RADS 3, but because it is also DC
3:29
positive, it's upgraded to PI-RADS 4. Now, I've got the comparison in the top row.
3:34
So this was from four years prior. And when we compare the prior and the current
3:39
one, so what you see is that there's not much change.
3:42
Essentially, the lesion has remained stable.
3:45
So what we have is PI-RADS lesion, which has been stable for the last four years.
3:49
But we know that PI-RADS is usually for standard detection, but it doesn't really
3:54
address or talk about the longitudinal change that has happened over
4:00
these two different time points. So for that, we use this scoring system.
4:06
It's called PRECISE. It's prostate cancer radiologic estimation of change in
4:11
sequential evaluation. So essentially, it allows us to monitor
4:16
these cases where there's not been any treatment or intervention, and we can
4:19
actually look at different time points and see if there's been any change compared
4:25
to the previous MRIs. So unlike PI-RADS, it allows for the serial assessment of
4:31
change between scans. So, this is PRECISE version one.
4:35
I think it was published about, basically, in 2017.
4:38
This is very similar to PI-RADS in the sense it also gives the one to five Likert
4:44
scale, and you can think of it like a traffic light system.
4:47
Essentially, PRECISE 3 is stable changes.
4:51
Anything below PRECISE 1 and 2 are changes are getting better.
4:56
And if it's PRECISE four and five, it's actually progress of disease.
5:00
And so, does it really predict outcomes?
5:02
So there are few studies at the moment, but I would like to highlight this
5:07
particular study in 2021, where they saw that if the PRECISE
5:13
scoring was one, two, three, meaning either it's stable or gotten better,
5:19
95% of these patients had no clinical progression.
5:23
Whereas if the PRECISE scoring was four to five, meaning there was either increase
5:28
in size of the lesion or a change in radiology stage, 61% of
5:34
these patients actually had clinical progression.
5:38
But then the version one did come with some limitations.
5:40
For example, there is no standardized way of measuring the lesion, so that
5:46
means that there can be high variability between radiologists who are reading the
5:50
scans. And there's also a bit of scoring ambiguity.
5:53
The criteria are not really clearly defined for PRECISE4 or PRECISE5, again,
5:59
which means that there can be quite variability between reading radiologists.
6:05
So the version two came up with changes.
6:08
One of the important change is integration of image quality, which was not in the
6:13
earlier version. Now, we're going to look at it later on, and there's also clear
6:17
definition of what baseline means.
6:19
For example, like the earliest MR.
6:23
And the PRECISE code three, which is stable changes, has been split into whether
6:28
it's visible change or a non-visible change, meaning if the lesion is visible and
6:33
the changes are stable, it's 3V, which is visible stable.
6:37
And say, if it has stable MR appearance, but we don't really see the lesion, it can
6:42
be categorized as 3NV. And also another new scoring system, which is PRECISEX,
6:48
which means that for whatever reason, the study is non-diagnostic and cannot be
6:53
really assessed. So this is the PRECISE version two.
6:58
Again, it's a five-point Likert scale.
7:00
It's just that the PRECISE3 scoring has now been split into visible and
7:05
non-visible, and then we do have this X category, say for example, if the image
7:09
quality is non-diagnostic. And there's also consensus reporting requirements and
7:14
also recommendations. One is dual comparison.
7:17
It's kind of similar to, say for example, MR-rectum, where we look at
7:22
post-treatment changes. We look at the immediate prior as well as the baseline MR.
7:27
Similarly, here for PRECISE, we do look at the immediate prior as well as the
7:32
baseline MR. And also the score assignment is, we do apply
7:38
PRECISE score for each lesion, and the highest score is the scoring of the entire
7:45
study. And we still apply PI-RADS category for each individual
7:51
lesion. And there is a bit more definition in terms of what increased means
7:57
in the version two. For example, if you look at the volume, significant volume
8:01
change has been defined as 50%. And also the minimal time interval between two
8:07
scans also is at least one year. So now, let's apply what we've just
8:13
seen in this particular case. So what you see is PI-RADS four lesion.
8:16
It's been stable since the last four years.
8:19
So essentially, we have a PI-RADS four lesion.
8:21
Because it's stable, we've given a scoring of PRECISE3, and because it's visible,
8:25
it's 3V. So the key points for this case is PRECISE allows for
8:31
longitudinal assessment of progression, unlike PI-RADS, and it's important to
8:36
compare with the recent prior as well as the baseline, and it's best to actually
8:41
talk about lesion in volume, which means that we need to give three dimensions
8:47
to be able to obtain the volumes. Okay. So now let's look at case two.
8:53
So I've got a 68-year-old male patient, previously Gleason 3+3, now on active
8:58
surveillance. This is a current study where he had increased PSA, and the question
9:03
was, is that progression? So what you see here is a small lesion at the right
9:08
posterior peripheral zone with protostatic diffusion Early enhancement, it's dark
9:14
on T2. So essentially what we're seeing is a small volume PIRADS 4 lesion.
9:19
So now that I've got the priors in the top row, so if we look at the prior also
9:24
PIRADS 4 and the current one, we can see that the lesion has increased in size.
9:29
It also looks a lot more conspicuous.
9:31
So essentially, there's progression from previous to current.
9:34
So this is still a PIRADS 4 lesion, but when we apply PI-RADS scoring, it's PI-RADS
9:39
4. So 4 means there is progression in terms of either increase in size
9:45
or increase in conspicuity of the lesion, or if there's a new lesion.
9:50
So what about image quality, because that's also part of the current
9:55
active surveillance assessments for MR.
9:57
So before we move into how to assess image quality, just to refresh our memories of
10:03
what the PIRADS version 2.1 technique actually is.
10:07
Say, these are the current guidelines, and for T2 images, the recommendation is the
10:13
slice thickness needs to be three millimeter without any gaps.
10:16
And the current recommendation says one axial and at least one orthogonal plane,
10:22
that is sagittal or coronal. But at least in my practice, most centers here we do
10:26
three-plane T2s. And for diffusion-weighted imaging, the slice thickness needs
10:32
to be four millimeter or less, and the high b-value needs to be at least 1,400 or
10:38
more, which can be either acquired or calculated.
10:42
And ADC map needs to be generated at least from two b-values, and the highest
10:47
b-value needs to be less than 1,000.
10:50
And for DCE, again, the slice thickness is three millimeter, the temporal
10:53
resolution needs to be 15 seconds or less, and with fat suppression.
10:58
And if there's no fat suppression, at least subtraction needs to be available.
11:02
So now, why does image quality matter?
11:06
So another study that published with PIQAL version one, which is the scoring system
11:12
for assessment. So what they've seen that is if the image quality is less, at least
11:18
a quarter of the cases had pathological upstaging, and there's also almost a
11:23
quarter of the cases were actually non-diagnostic.
11:26
And if you look at the middle number, it's about one-fourth of the cases where
11:30
PIRADS 5 was not assessed, meaning it was really challenging for assessment, for
11:36
example, for APE.
11:39
So how does this help? What does this mean for us actually when we do MR
11:45
readouts? So PIQAL is the current scoring system that's available for
11:51
quality assessment. So it stands for prostate imaging quality and MR
11:56
interpretation, for MR interpretation.
11:58
And say if the PIQAL scores are low, as we've seen in the previous slide, there's a
12:04
high chance of missing or under-detecting csPCAs.
12:08
And if the scoring is high, meaning the image quality is good, it is associated
12:13
with fewer equivocal PIRADS 3 classifications and also better readouts in terms of
12:19
local staging, especially when we're looking at extraprostatic extensions.
12:24
So this is the PIQAL version one. Again, this was a five-point scale,
12:29
but this has been revised recently with three scoring system, and it's quite simple
12:35
to understand, meaning if the scoring is one, essentially the study is inadequate.
12:41
If the scoring is two, it's acceptable, and of course, three is the best-case
12:45
scenario. So this is a scoring sheet available on the
12:51
paper here. So what essentially we do is to score each sequence
12:57
with these available metrics and then submit this into this chart.
13:03
So the main difference between PIQAL version one and version two, besides reduction
13:09
of the scoring system from five to three, version two can also be applied for
13:13
biparametric, not just multiparametric MRI.
13:16
But the cases today we're going to see are multiparametric, so we're just going to
13:20
stick to the bottom flowchart. And let's apply this flowchart to the
13:26
case two. So you have to take my word for it that all the scorings for T2 and DWI
13:31
were four, and then DCE was also optimal.
13:35
So essentially, we have a score of three, which means this is an optimal study.
13:40
But what about the scoring for the previous case, where I said the diffusion was
13:44
quite challenging to read? So the diffusion scoring was about two, but the
13:50
DCE was optimal. And because the T2 was also optimal, this can be
13:56
upgraded to two. So which means that it's still acceptable for us to make a read
14:01
from this study. So the key point here is, say, even if one of the
14:08
sequences is a bit of a challenging image quality, if the rest of the sequences are
14:14
okay, it can still be an acceptable scan.
14:17
So the key points for this case is the image quality assessment system that's
14:22
currently available is PIQAL version two, and this can be applied for both
14:26
biparametric as well as multiparametric MRI.
14:29
And you can kind of use DCE as a safety net.
14:33
But at least one of the sequences, either T2 or DWI, needs to score four out of
14:37
four. And if you think about it, it's quite intuitive, meaning if the image quality
14:42
is good, readouts are also going to be good.
14:46
So let's look at this case three for active surveillance.
14:50
So this is a 74-year-old male patient with 3 plus 4 equals 7
14:56
favorable
14:57
Gleason score, with now question of whether this is progression or not.
15:03
So this patient's on active surveillance, and what we see is this PIRADS 5 lesion.
15:08
We have the previous at the top row and the current at the bottom row.
15:11
So we've got T2 dark lesion, restricted diffusion, as well as positive DCE, so
15:15
PIRADS 5. And there's no APE, so the staging is T2.
15:21
So when we look at these two studies, there's not much difference.
15:24
So essentially what we're seeing here is PI-RADS scoring of 3, which means stable,
15:29
and we can still see the lesion, so this is visible, so it's 3V.
15:33
And when we apply the PIQAL scoring of image quality, everything is like tick box.
15:38
So this is a good study, so it's PIQAL 3 scoring.
15:44
And say, for example, for the same case, if we see extraprostatic extension in the
15:50
new study, that means that there is actually progression of staging from T2 to
15:56
T3. If that happens, this PI-RADS scoring would be PI-RADS 5.
16:00
So the key point for this case is essentially PIRADS and PI-RADS, they give really
16:06
different information. Say, for example,
16:11
the lesions can be PIRADS 5, but the PI-RADS can be 3.
16:15
But in the previous case, we've seen that it's a really tiny PIRADS 4 lesion, but
16:19
the PI-RADS scoring was four. So essentially, the PI-RADS talks about how things
16:24
have changed compared to the previous studies, where PIRADS actually talks about
16:28
the likelihood of a csPCA for a particular lesion at any time point.
16:34
So that's something to remember. And case four, I've got another case, also on
16:39
follow-up, but for watchful waiting.
16:40
So this is a 72-year-old male patient with increased PSA of
16:45
14.9. And the top row, I've got the previous imaging, and I've got the latest at
16:51
the bottom row.
16:53
And what we see here is multifocal disease, and this was a really high-grade lesion
17:00
for this 5 disease. And this is slightly different from active surveillance,
17:05
meaning
17:07
when you talk about watchful waiting, there's not a curative intent, unlike active
17:12
surveillance, where the intent is still to cure the patient if things change.
17:16
So this is mostly done, for example, for elderly patients or if their palliation
17:22
is required or just supportive measures, but not really a clear intent to treat.
17:27
So that's the difference between watchful waiting and active surveillance.
17:35
So now we'll switch gears to the next assessment examples.
17:41
So this is a case of prior radiotherapy, and the patient has come back with PSA
17:45
recurrence. So just a brief introduction of what scoring system's available for
17:51
whole gland therapy. So when we think about whole gland therapy, there are two
17:56
domains. One is whole gland radiotherapy, the other one is prostatectomy.
18:01
So there's slight differences between these two in terms of how we apply the
18:06
scoring system. And again, this is also a five-point Likert scale.
18:10
If then we say three, we're a little bit uncertain if there is recurrence.
18:14
When we say one and two, the likelihood of recurrence, our suspicion is low.
18:18
And when we say four and five, the suspicion is high.
18:23
But most of the times, at least in my practice, because I'm actually sitting in a
18:28
heartland PSMA. So most of these cases would go on to have PSMA, because
18:34
one of the limitations for applying this scoring system is that we're able to
18:39
assess only the prostate gland and not metastasis.
18:42
So
18:43
sometimes the patients may directly go to PSMA, or sometimes they may come for MR.
18:48
So the challenges for, say, radiotherapy assessment is
18:54
multifold. One, is because of radiotherapy, the gland itself shrinks, it becomes
18:59
fibrotic, and the T2 can be quite challenging to assess.
19:03
Sometimes we may even lose distinction between the transition zone and the
19:07
peripheral zone, and it makes it difficult to apply PIRADS framework.
19:12
And also if there are any, say, fusion markers or even--
19:18
Then there's a lot of artifacts and it's quite challenging to read the DWI.
19:23
So in these scenarios, DCE becomes the dominant sequence.
19:28
But for post-radiotherapy, we do have an option to look at DWI and DCE,
19:34
and we can drive the scoring depending on where we see the lesion best, whether
19:40
it's DWI or DCE. We'll just see an example.
19:43
And it's okay if you don't
19:46
remember this or get this, you can just have a look at it in the article, say, if
19:50
you choose to apply this scoring. So for this particular case, the scoring for DWI
19:55
was four, because what we saw was this positive DWI,
20:01
meaning this restricted diffusion, this positive DCE.
20:04
So when we go back and look at on the table, the scoring for DWI was four, and the
20:09
scoring for DCE was four. And I want to highlight that for this particular case, I
20:15
didn't have priors, so I didn't know where the primary site of the lesion was.
20:19
So if we don't know the primary site of the lesion, or if the new abnormality is
20:25
elsewhere, than the prior lesion, the scoring would be four.
20:31
But if it's at the same site of the lesion, the scoring would be five for each
20:35
individual sequence. So let's apply this framework for this particular case.
20:40
So we know that our scoring was four for both DCE and DWI, and
20:46
I do see the lesion quite well in DWI. So let's stick to the left side table.
20:51
So the scoring is four. So, next we look at the DCE.
20:55
So the DCE scoring was also four, and it just so happens that both these
21:00
abnormalities are matching, meaning they're at the same site.
21:03
If that happens, this is upgraded to five.
21:06
So that's how you apply a PIRR scoring to post-radiotherapy changes.
21:11
Again, local recurrence after radiotherapy, it usually occurs at the site of the
21:15
original tumor in more than 90% of the cases.
21:19
Then it kind of makes sense as to why if you see the abnormality of the same site,
21:24
the scoring for individual sequences would be scored five.
21:28
And after treatment with radiotherapy, the dominant sequences would be DCE and DWI.
21:34
And especially when the gland is really shrunken and fibrotic, it's important to
21:39
look for early enhancement and restricted diffusion in these glands.
21:43
T2 can be quite challenging to look at.
21:46
So let's look at the next case, which is a post-prostatectomy case.
21:50
And again, tumor site was not known, quite a remote surgery.
21:55
So what we see here is a large focal mass at the root of the seminal vesicle on
22:01
the right side. It shows early enhancement, quite bright, and also restricted
22:07
diffusion. So we know that this is a recurrence already, but how do we apply PIRR
22:13
in this case? Again, so when we look at the scoring matrix, both the DWI and DCE
22:18
have score four, and let's apply that
22:22
in this flowchart. So as I said, for radiotherapy and prostatectomy, the current
22:28
available assessment criteria is PIRR, but there's slight differences between these
22:33
two. So let's look at this chart. So the dominant sequence here is DCE.
22:38
So we said that it got score four and DWI was also scored four.
22:43
So essentially, the overall scoring is four.
22:45
So this is a recurrent disease at the right seminal vesicle bed with PIRR scoring
22:50
of four. So the important thing for prostatectomy is knowing where the site of
22:56
relapses commonly occur. So there are multiple sites, but these two sites are
23:00
really common. One is vesicourethral anastomosis, the other one is the residual
23:05
seminal vesicles. And for post-prostatectomy, unlike radiotherapy, DCE is
23:11
the dominant sequence.
23:13
So now we're switching gears to focal therapy, again, my most favorite part of the
23:18
talk. So this is case seven, and this is a proven decent grade three plus
23:24
four cancer. And what we see here is a focal lesion in the anterior right side of
23:29
the gland. And this case has come in for focal therapy assessment.
23:33
And there's a reason why I've given you biparametric MR images, shared only these
23:38
images here. So we've got a T2, we've got DWI, and ADC.
23:43
So if we just look at these images, this would be PIRADS-4, because the lesion is
23:48
less than one point four centimeter, and it's mostly anterior involving the
23:53
transition zone.
23:55
So when we look at focal therapy, there are quite a few options that are available.
24:01
So my experience is based on cryotherapy and IRE, so I'm just going to stick to
24:06
those two. So in cryotherapy, as the name implies, there's cycles of freezing and
24:11
thawing that cause cell death. But when we look at IRE, it usually uses electrical
24:17
pulses to cause ablation of the lesion.
24:20
So now let's relook at this case. So now we've got the DCE
24:27
image here. So when we compare the DWI, ADC, and the DCE, on DCE,
24:33
there's a lot more area that's enhancing early, which means that the lesion is much
24:38
larger than we thought it was before. So now it's PIRADS five.
24:42
But what's even more important is that it is periurethral in location.
24:46
It extends to around the urethra. So as I said,
24:51
at least in my previous institution, Singapore, where I've worked, there were two
24:55
options for focal therapy. One was cryotherapy, the other one was IRE.
25:00
So because this case has a lot of cancer extending to the periurethral
25:05
region, focal cryotherapy may not be the best option because in cryotherapy,
25:11
there's a warming catheter in the urethra, and because it's warming, we may not
25:15
freeze the cells
25:19
well enough for cell death around the periurethra.
25:23
So this is an ideal candidate for IRE.
25:26
So this is the importance of having the full set of assessment, and then decide as
25:31
to what treatment options this patient might benefit from.
25:35
So the main point for this case is the importance of DCE.
25:40
Again, if there's one takeaway from this entire talk, it's the importance of DCE,
25:45
especially in post-treatment cases.
25:47
So there are studies that have shown that DCE does reflect tumor extent
25:54
that's correlated well with histology, and especially now there is a lot of
25:58
interest in biparametric MRI, and if the consideration of treatment is focal
26:04
therapy, a DCE would be really helpful to be part of the assessment criteria.
26:11
So now let's look at how do we assess these patients after focal therapy.
26:15
So when we look at focal therapy, there are two different
26:19
areas where we can assess the gland.
26:22
So let's talk about the out-of-field recurrence.
26:25
So when we say out-of-field recurrence, this is the untreated gland we're talking
26:29
about. So we still use PIRADS version 2.1 in these areas.
26:33
But when we look for recurrence at the region of treatment, there are two options.
26:38
One is PiFAB and the other one is TARGET.
26:41
So what do we mean by in-field recurrence?
26:44
Either the recurrence is within the ablation cavity or just at the margins of the
26:49
ablation cavity. So as I said, there are two scoring systems that are available at
26:54
the moment. One is PiFAB. This was actually from a single institution from the
27:00
UK, whereas TARGET is actually multi-group consensus.
27:06
And for our dataset, we've applied both, and both really work well.
27:11
And this is a brief introduction of what PiFAB is.
27:15
So again, for focal therapy, DCE is the dominant sequence as well.
27:21
And for PiFAB, there's an order in which there's a recommendation as to how we
27:27
approach these cases. So we look at DCE first, and then we look at restricted
27:31
diffusion and T2, and each sequence has a specific criteria that needs to be
27:37
looked at. We'll have a look at in the next slide.
27:40
And unlike PIRADS or PIRR PI-FAB actually is a three-point
27:46
scoring system, one being low index of suspicion for recurrence, two meaning
27:51
intermediate findings, three meaning high probability of recurrence.
27:57
So this is the table that talks about as to what we need to look for
28:02
in each sequence. We'll look at this again with the case example.
28:06
So this is one-year follow-up for the same patient that we saw before, which shows
28:11
the expected typical post-ablation changes with cavity with a little bit of fluid
28:16
inside, but it doesn't really show any restricted diffusion, and I do not really
28:22
see any contrast enhancement. So let's apply PI-FAB for this case.
28:27
So as I said, the dominant sequence is DCE, so let's start there.
28:31
So we don't see any early enhancement, which means that it falls under this
28:34
category of no enhancement. So it's essentially a PI-FAB one score.
28:41
And we can look at the T2 and DWI as well.
28:44
There's absolutely no restricted diffusion, and this is the expected post-treatment
28:49
change for focal therapy. So the probability for recurrence is
28:55
quite low in this case, so this is a PI-FAB one. So what about TARGET?
28:59
So how do we look at TARGET? So TARGET is more of a two-tiered system.
29:03
So we first look at DCE, which is the major sequence, and then use DWI and T2 as
29:09
joint minor sequences. So each sequence, for example, whether it's DCE or
29:14
DWI or T2, they get three scores, whether, say for example, if you're looking at
29:19
DCE, are the findings non-suspicious? Are the findings equivocal?
29:24
Are the findings suspicious? And based on that, everything is summated to get a
29:28
five-point score. So again, it's a five-point score similar to other
29:35
scoring systems that we've seen. One and two, this index of suspicion is quite low,
29:41
three is intermediate, and four and five, index of suspicion is quite high.
29:46
So this is what I meant by giving a score for each and every sequence.
29:51
So let's take an example for DCE. So if we see no early enhancement or there is
29:56
some focal late enhancement, the scoring is one for DCE, which means that it's a
30:02
non-suspicious finding. But if the enhancement pattern is focal and nodular or
30:07
maybe thin and linear, it's a little bit equivocal, so that falls under two.
30:12
And if there's early enhancement, quite strong nodular enhancement, it's actually
30:16
suspicious features, that would be three.
30:21
So let's look at this case and see whether we can apply TARGET here.
30:27
So let's look at DCE first. So when we look at DCE, there's absolutely no early
30:30
enhancement, which means that the DCE score is non-suspicious, and which falls in
30:35
one. So the easiest way to approach TARGET is, say, for example, if the DCE is one,
30:41
that is there's nothing suspicious in DCE, the overall scoring can't be more than
30:45
one or two if you look at this table.
30:48
So it doesn't really matter,
30:51
the nitty-gritty of DWI and T2 doesn't matter because it wouldn't really go beyond
30:56
one or two, which is still low index of suspicion.
30:59
And if the DCE is three, and the cumulative score is already high suspicion, so
31:05
the gray area is essentially two, and then we need to look at how do we then
31:10
apply DWI and T2 to assess the overall score.
31:16
So for the key point for this case is for post-focal therapy, DCE is the dominant
31:21
sequence, irrespective of whether you're applying PI-FAB or TARGET.
31:27
So this is another case. Again, this is one-year post-cryotherapy.
31:31
The index lesion was Gleason three plus four, and this patient was treated with
31:35
focal cryotherapy. So what we see here is expected post-ablation change of the
31:40
right posterior epididymal zone.
31:43
And I don't see any DWI abnormality, nothing bright on DWI, but I do see a
31:49
tiny little bit of dot or dark focus in ADC, and this may be
31:55
really subtle, mild nodular enhancement on DCE.
31:58
So now there are some findings in this. So let's apply PI-FAB for this case.
32:03
So let's start with DCE. So we do see this subtle enhancement, which is
32:09
less than three millimeters. So the PI-FAB scoring would fall
32:13
in this mid-section. And when we look at T2, it's quite low, and then
32:19
DWI is also low. So this would be intermediate category for PI-FAB.
32:24
And what about TARGET? So let's start again with DCE, right?
32:28
So there's a small focus of enhancement, which is about
32:32
intermediate equivocal finding, which would be DCE two.
32:36
Now let's look at T2 and DWI. So the DWI is still low, so
32:42
which is non-suspicious, which is one.
32:44
And when we look at T2, it's also quite dark. Again, it's a score of one.
32:49
So essentially, we're looking at one, maybe two for DWI and T2.
32:54
So this would become TARGET three, so which means that it's still equivocal.
33:00
So the risk of or likelihood of recurrence in this case is equivocal.
33:04
So this patient was biopsied, and the biopsy turned out to be negative, and we do
33:08
have a few more years of follow-up for this patient with negative biopsy.
33:12
So the key point here is that fibrosis, especially in the setting of focal
33:17
therapies, can be quite low on ADC.
33:19
So it's always important to read ADC along with DWI.
33:23
So if we go back to this case, we do have some dark spot on DWI, but there's
33:27
nothing suspicious on-- I'm sorry, dark spot on ADC, but nothing suspicious on
33:33
DWI. So it's important to read them in conjunction and not just rely only on ADC in
33:38
this patient population.
33:41
And now moving to the last case. So I've got pre-treatment images on the top row,
33:47
and I've got the post-treatment images follow-up in the bottom row.
33:51
So pre-treatment, we see a focal lesion in the anterior right hemigland,
33:58
which extends to the periurethral region on DCE, and this was treated with IRE.
34:03
So the patient came back for one-year follow-up.
34:06
So what we see here is, this is the ablation area with dark
34:12
T2 signal. But at the margin of the ablation zone, there's something intermediate
34:17
that showed up, and that shows restricted diffusion and also very early
34:21
enhancement. And if we were to apply PI-FAB and TARGET here, so let's start with
34:26
PI-FAB. So this is a lot of abnormal large area of enhancement that corresponds
34:32
to DWI and T2. So this would be score three because it's
34:38
early focal enhancement, which is definitely more than three millimeter.
34:41
So this would be high index of suspicion of recurrence for PI-FAB.
34:44
And if we're applying TARGET, because the score of BCE is itself three, the
34:50
cumulative score, which is five, which means that again, there's high index of
34:53
suspicion for recurrence. And this was sampled, and this turned out to be Gleason
34:57
grade four plus four recurrence at just at the margin of the ablation zone.
35:02
So again, take-home point for focal therapy as such is DCE
35:08
is the main sequence or dominant sequence.
35:11
But any post-treatment assessment, if the DCE is positive
35:17
abnormal, that really needs to raise alarm bells.
35:20
And at the same time, if you have positive restricted diffusion, that kind of
35:24
increases our diagnostic confidence to call it as a recurrence.
35:28
So just to summarize what we've seen so far is there
35:34
are different scoring systems for different treatment assessments.
35:38
For example, if the patient is on active surveillance, the current scoring system
35:42
that's available is PRECISE, and which also incorporates image quality, which is
35:46
PI-RADS well, and the current version is two.
35:48
And for whole gland therapy, whether it's prostatectomy or radiotherapy, we're
35:53
looking at PI-RADS. And the slight difference is if you were to choose to apply
35:57
this scoring as to how you approach prostatectomy versus radiotherapy.
36:01
And for focal therapy, currently, there are at least two scoring systems available.
36:07
One is PI-FAB, which is a three-point scale and scoring system, and TARGET is a
36:12
five-point scoring system. But irrespective of what we choose to use, the
36:18
dominant sequence is DCE. And as I said, based on a PIRADS
36:24
version two point one technique, the recommendation is having an axial T2 and at
36:28
least one orthogonal plane. But if you're looking at post-treatment changes, it's
36:32
good to have all the three planes And DCE becomes the dominant sequence for most of
36:38
these post-treatment assessment changes.
36:40
And when we're looking at ADC, especially for post-focal therapy, it's important to
36:45
read it along with the DWI, because sometimes fibrosis can also have low ADC.
36:50
Again, these are all still maturing systems, and you may or may not choose to
36:57
use these grading systems depending on your local practice.
37:00
But even if we don't use these scoring systems, the principles behind all
37:06
these systems are actually quite helpful for us to detect any recurrent cancers,
37:11
and that can be incorporated into how we approach these scans.
37:16
And these are my acknowledgments.
37:18
So most of my focal therapy work was from Singapore, and that's my crew from
37:22
Singapore. And
37:25
also my current residents, both from Sydney and Melbourne, have helped me with some
37:29
of the prostate work that went on into this PowerPoint as well.
37:33
And with that, thank you very much, and I've included my email.
37:37
If you want to get in touch, please feel free to do so.
37:43
And with that, I'm open for some questions and just going to have a quick look at
37:49
the chat to see if there are any questions.
37:54
Yeah. Thank you so much for that lecture.
37:55
We've got a question in the Q&A box if you can
37:59
click that.
38:02
Yeah. So I have a question here. So for both Pi-FAB target and PIR
38:08
post-radiotherapy scores, is there a time interval post-procedure that the MR will
38:13
be repeated? So for post-radiotherapy, I think there's enough evidence to
38:20
show that early on, there's still a lot of granulation tissue or reactive changes
38:26
that could result in spurious or challenges reading scans.
38:30
At least the current recommended time interval is at least three months for
38:34
radiotherapy. But oftentimes, the follow-up usually comes back within a year.
38:39
And in my previous institution in Singapore, our follow-ups are usually a minimum
38:44
time interval of one year, unless there's a high index of
38:50
suspicion for PSA and DRE. So usually, that's what we follow.
38:55
The next question is granulomatous prostatitis versus CSPC and pre
39:00
and post-treatment. This is always a challenge when we're looking
39:06
at granulomatous prostatitis versus CSPCA.
39:10
So the cases that we've come across for granulomatous prostatitis have had a
39:15
positive history for BCG oftentimes. So that's definitely helpful.
39:22
But otherwise, it can be quite challenging because granulomatous prostatitis can
39:26
also look like PIRADS five lesions, sometimes really hard to tell.
39:31
Okay. I think we'll close. Really appreciate you being here and giving us your time
39:36
for this awesome lecture.
39:38
Yeah. Thank you so much for having me. Thank you.
39:40
Of course, yes. And thanks for everyone else for signing on and participating in
39:43
today's noon conference. You can access a recording of today's conference and all
39:47
our previous ones by creating a free account.
39:50
We'll also email out a link to the replay later today.
39:53
Be sure to join us next week on Thursday, October 8th at 12:00 PM Eastern, where
39:58
Dr. Kevin Chang will deliver a lecture entitled "Diffuse Liver Disease." You can
40:02
register for that on vidality.com.
40:04
Follow us on social media for updates on future noon conferences.
40:07
Thanks again, and have a great day.